SCHEMBL1102020

SCHEMBL1102020

CNS(=O)(=O)c1ccc(NC(C)=O)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.73
CA2 P00918 2/20 0.73
MMP1 P03956 1/20 0.73
MMP2 P08253 1/20 0.73
MMP9 P14780 1/20 0.73
MMP8 P22894 1/20 0.73
MMP13 P45452 1/20 0.73
POLB P06746 1/20 0.69
CA12 O43570 1/20 0.65
CA9 Q16790 1/20 0.65
IDO1 P14902 6/20 0.61
F2 P00734 1/20 0.61
PRSS1 P07477 1/20 0.61
PRSS2 P07478 1/20 0.61
PRSS3 P35030 1/20 0.61
PKM P14618 2/20 0.61
MEN1 O00255 2/20 0.59
ALDH1A1 P00352 2/20 0.59
KMT2A Q03164 2/20 0.59
MAPK1 P28482 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11242568 0.90 LMNA (0.69) CA1CA2MMP1MMP2MMP9
SCHEMBL8224012 0.85 CA1 (1.00) CA1CA2MMP1MMP2MMP9
SCHEMBL28550935 0.85 CA1 (0.73) CA1CA2MMP1MMP2MMP9
SCHEMBL10992157 0.85 CA1 (0.73) CA1CA2MMP1MMP2MMP9
SCHEMBL2372596 0.83 CA1 (0.71) CA1CA2MMP1MMP2MMP9
SCHEMBL10155593 0.83 KMT2A (0.69) CA1CA2MMP1MMP2MMP9
SCHEMBL15798330 0.83 CA1 (0.71) CA1CA2MMP1MMP2MMP9
SCHEMBL394378 0.82 RXFP1 (0.54) CA1CA2MMP1MMP2MMP9
Acedapsone SCHEMBL152710 0.82 PKM (0.85) CA1CA2MMP1MMP2MMP9
SCHEMBL11590063 0.80 CA1 (0.67) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200148650-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS Epizyme, Inc. 2020-05-14 US disclosed
US-20160312253-A1 Compounds for Increasing Lipid Synthesis and Storage INVITROGEN CORPORATION 2016-10-27 US disclosed
US-20160235685-A1 PHOTOSENSITIVE CAPSULES AND COSMETIC AND PHARMACEUTICAL USE THEREOF L'OREAL (FR) 2016-08-18 US disclosed
CN-105801582-A Novel dihydro pteridinone derivative, preparing method thereof and application to medicine 合肥工业大学 2016-07-27 CN disclosed
US-20140301999-A1 BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS DECODE GENETICS EHF (IS) 2014-10-09 US disclosed
US-8841282-B2 Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-23 US disclosed
US-8586589-B2 Piperidine and piperazine phenyl sulfonamides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-11-19 US disclosed
US-8546392-B2 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases UNIVERSITAET DES SAARLANDES (DE) 2013-10-01 US disclosed
US-8546392-B2 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases UNIVERSITAET DES SAARLANDES (DE) 2013-10-01 US disclosed
US-20130184258-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-18 US disclosed
US-20020058710-A1 SUBSTITUTED CINNAMIC, ACID GUANIDIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, AND MEDICAMENT COMPRISING THEM AVENTIS PHARMA DEUTSCHLAND GMBH. 2002-05-16 US disclosed
WO-2002024637-A1 SUBSTITUTED CINNAMIC ACID GUANIDIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT, AND TO A MEDICAMENT CONTAINING THESE COMPOUNDS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-03-28 WO disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
EP-0726903-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-07-16 EP disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed
EP-0303415-B1 Herbicidally active phenoxy-alkanecarboxylic acid derivatives SUNTORY LTD (JP) 1994-11-30 EP disclosed
US-5205855-A Postemergence, preemergence herbicides SUNTORY LIMITED (JP) 1993-04-27 US disclosed
US-4976773-A SELECTIVITY BETWEEN MONOCOYLEDON PLANTS SUNTORY LIMITED (JP) 1990-12-11 US disclosed
EP-0303415-A2 Herbicidally active phenoxy-alkanecarboxylic acid derivatives SUNTORY LIMITED (JP) 1989-02-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160312253-A1 Compounds for Increasing Lipid Synthesis and Storage FASN, LIPC, SREBF2 CA1 4547/4885CA2 3458/4885MMP1 4399/4885
US-20160235685-A1 PHOTOSENSITIVE CAPSULES AND COSMETIC AND PHARMACEUTICAL USE THEREOF KRT18, CEP170, DSG1 CA1 2022/4885CA2 1220/4885MMP1 2648/4885
US-20020058710-A1 SUBSTITUTED CINNAMIC, ACID GUANIDIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, AND MEDICAMENT COMPRISING THEM GANC, GMPS, GCDH CA1 2872/4885CA2 608/4885MMP1 3619/4885
US-20130184258-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels SCNN1G, KCNN3, KCNN2 CA1 541/4885CA2 182/4885MMP1 4023/4885
US-20140301999-A1 BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS PDE4A, PDE4B, PDE3B CA1 2284/4885CA2 1643/4885MMP1 365/4885
US-20200148650-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS SMYD3, SMYD2, SNRPD3 CA1 2424/4885CA2 1009/4885MMP1 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.